This Phase 1, multicenter, open-label trial will assess the safety and feasibility of IFx-Hu2.0 as adjunctive therapy to pembrolizumab in adult patients (≥18 y…

Advanced Or Metastatic Merkel Cell Carcinoma

~Estimated

~$10 – $8,750

TuHURA Biosciences, Inc.NCT06940440

Phase 2

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of IFx-Hu2.0 as an Adjunctive Therapy to Pembrolizumab in Checkpoint-Inhibitor Naïve Participants With Advanced or Metastatic Merkel Cell Carcinoma

This Phase 2/3, multicenter, randomized, double-blind, placebo-controlled trial will evaluate the Objective Response Rate (ORR) of IFx-Hu2.0 as an adjunctive t…

Advanced Or Metastatic Merkel Cell Carcinoma

~Estimated

~$10 – $8,750

TuHURA Biosciences, Inc.NCT06947928